36725-28-7 Usage
Description
6-(4-Aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone, also known as AMDP3, is a chemical compound with a unique structure that features a pyridazinone ring system. It is characterized by the presence of an aminophenyl group attached to the 6th position and a methyl group at the 5th position. 6-(4-Aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone has been found to have significant biological activities, making it a promising candidate for various pharmaceutical applications.
Uses
Used in Pharmaceutical Industry:
6-(4-Aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone is used as a cardiac troponin effecter for the activation of cardiac muscle contractions. It serves as an analogue to Levosimendan (L378000), a positive inotropic agent with vasodilating activity. This application is particularly relevant in the treatment of heart failure and other cardiovascular conditions where the enhancement of cardiac contractility and the improvement of blood flow are essential.
Used in Cardiovascular Applications:
In the field of cardiovascular medicine, 6-(4-Aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone is utilized for its ability to stimulate cardiac muscle contractions. This makes it a valuable compound in the development of new therapeutic strategies for managing heart failure and other related conditions. Its positive inotropic and vasodilating properties contribute to its potential as a treatment option for patients with compromised cardiac function.
Used in Drug Development:
The unique structure and biological activities of 6-(4-Aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone make it an attractive candidate for drug development. Researchers can explore its potential in designing new drugs targeting various cardiovascular diseases, as well as other conditions that may benefit from its specific mode of action. 6-(4-Aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone's ability to activate cardiac muscle contractions and its similarity to Levosimendan suggest that it could be a useful starting point for the development of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 36725-28-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,7,2 and 5 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 36725-28:
(7*3)+(6*6)+(5*7)+(4*2)+(3*5)+(2*2)+(1*8)=127
127 % 10 = 7
So 36725-28-7 is a valid CAS Registry Number.
InChI:InChI=1/C11H13N3O/c1-7-6-10(15)13-14-11(7)8-2-4-9(12)5-3-8/h2-5,7H,6,12H2,1H3,(H,13,15)
36725-28-7Relevant articles and documents
ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS
-
Page/Page column 329-330, (2021/01/29)
Conjugate of a binder having formula (AA) wherein AB stands for a binder, Z' stands for a linker, D stands for an active component which is a NAMPT inhibitor and its use as pharmaceuticals.
DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS
-
Page/Page column 204, (2018/05/27)
Compounds of formula (I) which are nicotinamide phosphoribosyltransferase (NAMPT) inhibitors and their use for the treatment of hyperproloferative diseases and/or disorders responsive to induction of cell death.
PROCESS FOR PREPARING LEVOSIMENDAN AND INTERMEDIATES FOR USE IN THE PROCESS
-
Page/Page column 11, (2011/02/24)
In an embodiment, the present invention provides a process for preparing (-)-6-(4- aminophenyl)-5-methylpyridazin-3-(2H)-one, which process comprises: a) reacting racemic 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone of formula (Il) with a chiral tartaric acid derivative to obtain a diastereomeric salt of (-)-6-(4- aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone and the chiral tartaric acid derivative; and b) reacting the diastereomeric salt with a base to obtain (-)-6-(4- aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone. The (-)-6-(4-aminophenyl)-4,5- dihydro-5-methyl-3-(2H)-pyridazinone may be used to prepare levosimendan.